PRESS RELEASES

Menlo Park, California, July 5, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics in oncology and infectious diseases, […]

Menlo Park, California, June 9, 2015: 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in

Menlo Park, California, February 19, 2015. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in

Menlo Park, California, December 30, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in

Menlo Park, California, December 2, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in

Barcelona, Spain, November 19, 2014. 3-V Biosciences, Inc., (3-V), a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in

Menlo Park, California, October 2, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in

FASN Anti-Tumor Candidate in Clinical Development Menlo Park, California, December 4, 2013. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing

Menlo Park, California, November 21, 2013. 3-V Biosciences, Inc. (3‐V), a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways

3-V’s Small Molecule Tumor Metabolism Inhibitor Demonstrates Single-Agent Activity; Halts Tumor Growth and Induces Tumor Regression Menlo Park, California, October